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ABSTRACT
RELATIONSHIP BETWEEN
GLUCOSE-6-PHOSPHATE DEHYDROGENASE ACTIVITY
AND HORMONE DEPENDENCY
IN RAT MAMMARY CANCER
Lila S. Berry, M. S.
Morehead State University, 1985
Some breast cancers will regress following endocrine
manipulation and are considered to be hormone dependent.
It has been demonstrated that mammary tumors containing
estrogen receptors are likely to exhibit hormone dependency.

Additional research has revealed the prese~ce of

proteins whose synthesis is promoted by estrogen.

Pro-

gesterone receptor is one such molecule, and its measurement has been used as a predictor of response to endocrine
therapy.

Another protein whtch has been investigated as a

possible indicator of hormone dependency is glucose-6phosphate dehydrogenase (G6PD), an essential enzyme in
the hexose monophosphate shunt of glucose metabolism.
In this investigation mammary cancer was induced in
rats with the carcinogen 7, 12-dimethylbenz(a)anthracene
CDMBA) .

Mammary lesions which developed were biopsied and

assayed for G6PD activity by means of spectrophotometry.
Bilateral ovariectomies were performed on these rats at
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this time.

Tumors which regressed following ovariectomy were

classified as hormone dependent, while those which continued
to grow were considered hormone independent, or autonomous.
At the end of a 3-18 week period, the animals were sacrificed, and second G6PD assays were conducted on the tumors.
G6PD activity in hormone-dependent tumors was significantly higher than the activity of hormone-independent
tumors prior to ovariectomy (p < .001).

After surgery,

G6PD activity in the hormone-dependent group declined considerably and was not significantly different from that of
the autonomous group.

Correlation between enzyme activity

and percentage of tumor regression within the hormone-dependent group was not significant.
Some regressing tumors showed signs of regrowth during
the period of observation.

This small group of neoplasms

demonstrated G6PD activity levels similar to those of the
non-recurring hormone-dependent tumors both before and after
ovariectomy.

A significant correlation between enzyme ac-

tivity and length of remission could not be demonstrated.
Results of this study support the association of high
G6PD activity with hormone dependency in mammary cancer.
Further research is necessary to establish reliable standards for the classification of tumors based on this enzyme assay.
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INTRODUCTION
Hormone dependency in breast cancer has been studied
for many decades; however, the relationships between the
various hormones and neoplasia remain incompletely understood,

Endocrine ablation experiments have yielded sig-

nificant clues.
Toward the end of the last century, dramatic remission of recurrent breast cancer following bilateral
ovariectomy was reported (1).

Since the source of ova-

rian steroids was removed by this procedure, these cancers
were termed "hormone dependent."

Many years later, simi-

lar results were achieved among post-menopausal women
through bilateral adrenalectomy.

It was believed that

regression occurred as a result of the elimination of
adrenal cortical androgens which were aromatized to estro9ens by peripheral tissue, as well as by the tumor itself

(2, 3).

Another operation which met with some success was

hypophysectomy.

This surgical procedure resulted in the

removal of tropic hormones which stimulate steroid synthesis and also of pituitary prolactin, a hormone implicated in breast cancer development.
In addition to these surgical treatments, chemical
hormonal ablations have been introduced as therapy for
hormone-dependent cancers.

Anti-estrogens employed have
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included clomiphene, nafoxidine and tamoxifen (4).

Med-

ical adrenalectomy has been accomplished by the administration of aminoglutethimide, which blocks the formation
of glucocorticoids (5) and, additionally, inhibits the
activity of aromatase (6).
Cancer remission has also been induced, primarily in
post-menopausal women, by pharmacological doses of estrogen (or estrogen agonists, such as diethylstilbestrol) ..
The reason for this paradoxical effect is unclear, but
some have proposed that the large amounts of estrogen inhibit the activity of prolactin (7, 8).
Unfortunately, endocrine manipulations produce objective remissions in only about 30% of advanced breast
cancers.

Results of combined studies employing various

endocrine therapies are summarized in Table 1.
not all breast cancers are hormone dependent.

Evidently,
Those which

are tend to confer a survival advantage upon their hosts,
since hormone-dependent tumors are generally less aggressive than autonomous tumors.
Researchers have developed animal models to study the
cell biology of hormone dependency in cancer.

Nucleophilic

aromatic hydrocarbons have long been implicated in carcinogenesis.

These substances, or their metabolites, are usu-

ally electron donors and readily form associations with nucleophiles, altering the cellular DNA (9).

One hydrocarbon

3

Table 1.

Objective Response Rates
to Various Forms of Endocrine Therapy
Taken from Henderson and Canellos (4)

Therapy

No. of
Patients

Response
Rate (%)

Estrogens

1683

26

15-38

Androgens

2250

21

10-38

Progestins

508

25

9-43

Corticosteroids

589

23

0-43

Oophorectomy

1674

33

21-41

Adrenalectomy

3739

32

23-46

Hypophysectomy

1174

36

22-58

Tamoxifen

504

35

22-49

Nafoxidine

283

31

28-38

Clomiphene

167

28

16-39

280

31

25-50

Range of
Response Rate

Hormones

Ablation

Antiestrogens

Medical Adrenalectomy
Aminoglutethimide
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used extensively for the induction of rat mammary tumors
is 7, 12-dimethylbenz(a)anthracene (DMBA).

Mammary cancer

can be induced in rats by a single feeding of DMBA (10),
and the tumors produced are usually hormone dependent (11).
It has been discovered that DMBA, when administered intragastrically, accumulates in the ovaries, adrenals and adipose tissue (12), which may reflect the tendency of the
induced mammary tumors to be hormone dependent.
Steroid Action Mechanism
During the 1960's the mechanisms by which steroid
hormones act on their target cells became better understood with the discovery of intracellular receptor proteins

(13).

A current model for steroid action is il-

lustrated in Figure 1.
The secreted hormone, bound to a steroid binding
globulin, is systemically transported to the target cell.
Here the steroid molecule is dissociated from its binding
globulin and, being lipophilic, readily penetrates the
cell membrane.

In the cytosol the steroid is bound to

a receptor protein.

The steroid-receptor complex is trans-

located to the cell nucleus where it becomes attached to
the chromatin, activating the DNA promoter region which
stimulates the transcription of RNA.

The RNA transcript

is processed, and rnRNA is transported to the cytoplasm
where it becomes attached to ribosomes, effecting the
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Figure 1.

Model of Steroid Action Mechanism
The steroid is designated as Sand the receptor (a dimer) as RA and RB.
Taken from O'Malley (14)
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translation of a new protein.

This new protein alters

the functioning of the target cell (14).
Although the location of estrogen receptor in the
cytosol has recently been questioned (15, 16), the model
described above is generally accepted as an explanation
of the steroid mechanism.

The presence of receptor in a

target cell is considered to be an indication of normal
endocrine responsiveness.

Loss of receptor during malig-

nant transformation results in ~he abolition of endocrine
control and elimination of hormone dependency (17).
Breast Cancer Evolution
The presence of a spectrum of hormone dependency among
breast tumors has been described by Manni (18).

Among the

prevailing theories of mammary cancer evolution is the development and selection of dedifferentiated, highly proliferative, autonomous clones from an initially hormonedependent cell line (19).

This model is supported by the

research of Kim and Depowski (.20), who, using transplantable
rat tumor, reported the progression from hormone dependency
to autonomy accompanied by the emergence of distinct clones
with different hormonal responsiveness.

Recent receptor

studies (21) lend further support to this concept.
An alternative model has been proposed by Selby et al.

(22), who have suggested the existence of undifferentiated
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tumor stem cells, some of which give rise to differentiated, less proliferative, hormone-responsive progeny.

The

successful secondary hormonal therapy in patients whose
cancer has relapsed following a response to previous endocrine manipulation ban be attributed to this stern cell
model, and chemotherapy sequential to hormone treatment is
proposed as a means of eliminating the remaining stern cell
population.
Hormonal Influences and Interactions
Animal models and in vitro studies of human cell lines
have furnished clear evidence of hormonal influences on the
development and regression of mammary carcinoma.

Depriva-

tion of sex hormones in the rat has produced tumor regression
marked by a sharp increase in the production of prostaglandin
E2 and of cyclic AMP (23).

A high molecular weight protein

associated with tumor regression has been found to be phosphorylated by a cAMP-dependent protein kinase (24).
It is generally recognized that estrogen promotes cell
proliferation in both normal and malignant mammary tissue.
Some research has furnished evidence that this stimulatory
activity may be a negative effect resulting from the neutralization of a serum-borne growth inhibitor (25).
There has been some disagreement concerning the role
of estrogen in tumor promotion.

Some studies of rat tumors
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have suggested a secondary function of stimulating the
release of prolactin by the pituitary (26).

Both estro-

gen and prolactin have been demonstrated to counteract
inhibitory effects of underfeeding on rat tumor growth
(27), and both hormones have been regarded as essential
for the development and growth of these tumors (28).
The receptor for prolactin in rat tumors was first
described by Costlow et al. in 1974 (29).

Hypophysecto-

mized animals undergo tumor regression which is not counteracted by estrogen administration (30).

Anti-prolactin

treatment has resulted in ~oth suppression of tumor formation (31, 32) and in regression of induced rat mammary
tumors

(33).

However, Leung et al. have reported that

tumors regressing following ovariectomy or adrenalectomy
were not stimulated by prolactin when administration was
delayed (34).

A secondary role for prolactin has been

proposed, since this hormone has been shown to increase
the concentration of estrogen receptor (35).
Linkage of prolactin to human mammary cancer has been
more equivocal.

Anti-prolactin therapy rarely results in

objective remissions, and some patients maintain high levels
of serum prolactin despite tumor regression following pituitary stalk section (17).
,The presence of prolactin receptors in human breast
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tumors was established fairly recently (36).

Shortly

thereafter, Malarkey et al. reported in vitro cell proliferation following prolactin administration in a cell
line derived from a breast cancer patient (37).

It has

been suggested that selection mechanisms may operate to
determine whether a particular tumor population responds
to prolactin, estrogen or other hormones (38).
Supportive roles in mammary cancer biology have been
suggested for a variety of hormones.

These include pro-

gesterone (39, 40), androgens (41), glucocorticoids (42),
growth hormone (43), insulin (44) and melatonin (45).

The

possible interrelationships among all the various hormones
mentioned above illustrate the complexity of breast cancer
physiology.

Hormone dependency apparently involves a con-

stellation of endocrine-mediated events.
Steroid Receptor Evaluations
The discovery of steroid receptors was shortly followed by the development of assay techniques to determine
receptor concentrations and binding affinities in both
nuclear and cytosolic fractions.

Estrogen receptor could

now be measured by employing radioligand competitive binding
techniques and Scatchard analysis (46).
When breast tumors were evaluated for estrogen receptor, it was found that_ some contained measurable levels
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of receptor, while others did not.

Of those patients with

tumors positive for estrogen receptor, between 50 and 60%
responded to endocrine therapy.

(See Table 2.)

With the refinement of receptor assay methods, it became standard procedure to test primary breast cancers for
the presence of estrogen receptor.

Results of this assay

could then be used at the time of recurrence to better ascertain whether the patient was likely to benefit from hormonal manipulation.

A patient whose tumor lacked estrogen

receptor could be started on a regimen of chemotherapy.
Since a considerable proportion of tumors possessing
estrogen receptors nevertheless fail to· respond to hormone
',

therapy, investigators have inferred that this group of.
ER+ tumors contains non-functioning receptors, i . e . , the
steroid mechanism is defective (48).

There is evidence

that this defect occurs at some point after estrogen-receptor binding has taken place (49, 50).
In order to determine whether the estrogen mechanism
is functioning, researchers could test for the presence of
progesterone receptor, the synthesis of which is stimulated
by estrogen.

Horwitz et al. proposed it as a marker for

hormone dependency (51).

When tumors are measured for both

estrogen receptor and progesterone receptor, those positive
for both receptors exhibit a hormone responsiveness rate of

11

Table 2.

Clinical Correlations of Breast Cancer
Remissions to Endocrine Therapy and
Estrogen Receptor Content
Taken from DeSombre and Jensen (47)

Remissions/Cases
Investigators

ER+ (%)

ER- (%)

Blarney et al.

13/30 ( 43)

Dao & Nemoto

64/119

Degenshein et al.

27/45

DeSombre & Jensen

39/62 ( 6 3)

4/108 (4)

Lippman & Allegra

77/139 ( 55)

6/105

Maass et al.

64/93

Manni et al.

68/105

McCarty et al.

32/58 (55)

7/40 (17)

Nomura et al.

29/45 ( 6 4)

0/36

Osborne et al.

69/145

Paridaens et al.

14/31 ( 45)

Rubens & Hayward

46/136

Singhakowinta et al.

20/30 ( 6 7)

2/23

Skinner et al.

17/30 ( 5 7)

5/44 (11)

Wittliff

37/67 (55)

0/44

( 0)

Young et al.

46/83 (55)

6/22

( 2 7)

Totals

(54)
( 6 0)

( 6 9)

662/1218

( 6 5)

( 4 8)

( 3 4)

( 5 4)

5/27 (19)
4/56

(7)

1/15 (7)

(6)

3/76 (4)
2/21 (10)

(0)

5/53 ( 9)
0/18

(0)

5/55 ( 9)
(11)

55/743 (7)
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Table 3. Clinical Correlations of Breast Cancer
Remissions to Endocrine Therapy and
Estrogen and Progestin Receptor Content
Taken from DeSombre and Jensen (47)

Remissions/Total Cases
ER+PR-

Allegra et al.

11/14

8/14

Brooks et al.

4/6

2/7

10/13

18/31

Degen she in et al.

26/33

3/14

1/1

0/14

King

10/11

3/15

0/2

2/9

Manni et al.

15/24

3/5

McCarty et al.

33/40

2/20

Osborne et al.

16/20

14/45

Skinner et al.

9/12

Dao

&

Nemoto

Young et al.
Totals

ER-PR+

ER-PR-

ER+PR+

Investigators

0/4

0/12

2/28

0/2
1/3
3/20

2/6

2/3

3/30

20/29

3/14

1/2

2/9

154/202

58/171

(78%)

( 34%)

5/15
(33%)

12/124
(10%)

13

75-80%.

(See Table 3.)

Progesterone receptor assay, con-

sequently, has become an additional diagnostic tool with
which. to assess hormone dependency.

Indeed, some investi-

gators regard th.e level of progesterone receptor as a more
reliable indicator than estrogen receptor (52).

One pro-

posed course of advanced breast cancer therapy based on
positive estrogen and progesterone receptor findings is
outlined in Table 4.
Glucose-6-Phosphat~ Dehydrogenase
Receptor assays involve difficult techniques and complicated analyses (54).

Many hospitals• are not equipped

for these procedures ·and must send frozen· biopsies elsewhere.

Since temperature changes during and after surgery

affect receptor stability (55, 56), assay results may be
imprecise.

Therefore, some researchers have sought to

identify additional proteins with which to test the estrogen mechanism.
Ringler and Hilf (57) demonstrated that estrogen promotes the synthesis of the enzyme glucose-6-phosphate dehydrogenase in transplantable rat mammary tumor and that
this increase is shortly followed by an increase in enzyme
activity.

Glucose-6-phosphate dehydrogenase (G6PD) is an

enzyme involved in the hexose monophosphate (HMP) shunt of
glucose metabolism.

Figure 2 illustrates this particular
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Table 4.

Proposed Sequential Hormonal Therapy
Taken from Osborne and McGuire (53)

Premenopausal Women
First line

Bilateral ovariectomy

Postmenopausal Women
Tamoxifen

or tamoxifen
Second line

Tam6xifen or bilateral ovariectomy

Estrogens
Medical adrenalectomy
or major ablative
surgery
High-dose medroxypro. gesterone acetate

Third line

Medical adrenalectomy
or major surgical

Androgens
Low-dose progestins

ablation
Fourth line

Androgens, progestins

Fifth line

Glucocorticoids

Glucocorticoids

15

glycolytic pathway.
In mammals the significance of the HMP shunt lies
chiefly in some of the intermediate products formed.

Par-

ticularly important are the pentoses, which are incorporated into nucleotides, and NADPH, a coenzyme essential for
the synthesis of nucleic acids, fatty acids and steroids.
The rate-limiting reaction (circumscribed in Figure 2) is
catalyzed by G6PD.
High levels of G6PD activity are found in the ovary,
liver and lactating mammary gland, as well as in adipose
tissue (59).

Hormone-dependent mammary tumors in mice ex-

hibit levels somewhere between those found in virgin and
lactating mammary gland (60).

The hormone-dependent human

breast cancer cell line MCF-7 has demonstrated a higher
level of activity than a benign tumor line (.61L
Human breast cancer studies comparing estrogen receptor
content with G6PD activity have resulted in conflicting reports.

Poulsen and Frederiksen (62) could find no relation-

ship between the two parameters.

Hilf et al.

(63) reported

a lower level of enzyme activity in estrogen-receptor positive cancers than in those which were ER negative.

However,

opposite results were obtained by Daehnfeldt and Schulein
(64) and by Duffy and Duffy (65).
Some explanation of these apparent contradictions may
have been supplied by the research of Messeri et al.

(66).
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Hexose Monophosphate Shunt
Taken from Mahler and Cordes (58)
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These studies seem to indicate the existence of two groups
among the ER positive human cancers:

those with high levels

of G6PD activity and those whose enzyme activity is essentially the same as that observed among ER negative cancers.
These results suggest that those samples with high enzyme
activity may represent hormone-dependent tumors, in which
the estrogen mechanism is functioning, i . e . , producing the
appropriate protein.
Association of high levels of G6PD activity with hormone dependency has been demonstrated in experimental rodent
mammary tumors (60).

A significant decline in the enzyme ac-

tivity of hormone-dependent tumors following ovariectomy has
been reported (67, 68).

Research by Briand and Daehnfeldt

(60) has indicated that G6PD activity levels in autonomous
tumors do not increase upon administration of estrogen, a
finding supportive of the steroid action model.
In addition to its usefulness as a predictor of hormone
dependency, G6PD activity (along with the activity of some
other enzymes) has been proposed by Savlov et al. as a predictor of responsiveness to adjuvant chemotherapy (69).

Pa-

tients with low levels of enzyme activity were shown to be
more likely to experience recurrence within one year following chemotherapy, regardless of estrogen receptor status.
While induced rat mammary cancers differ in some respects
from human breast carcinoma (propensity to metastasize, for

18

example), the basic biology of hormone dependency is similar.
This study will attempt to determine if G6PD activity is an
accurate predictor of hormone dependency in DMBA-induced rat
tumors.
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MATERIALS AND METHODS
Tumor Induction
Immature female Sprague-Dawley rats were obtained
from Harlan Industries, Indianapolis, IN.

They were main-

tained in a temperature and light-controlled environment
and supplied with water and Purina Rodent Chow (RalstonPurina Co., St. Louis, MO) ad libitum.
At age 50 :I: 1 days, under light ether anesthesia,
these animals received a single dose of 20 mg. 7, 12-dimethylbenz(a)anthracene in 2 ml. of peanut oil emulsion
by gastric intubation.

Beginning six weeks after carcino-

gen administration, the rats were palpated weekly for
tumors.

The first tumors were detected two months fol-

lowing DMBA treatment.
Surgery
An animal was considered for surgery when at least
one tumor exceeded 1 cm. in diameter.

The rat was anes-

thetized with an intra-peritoneal injection of sodium
pentobarbital (Butler Co., Columbus, OH) at a dose of
4 mg. per 100 g. of body weight.
measured with calipers.

All tumors were then

The number of tumors ranged

from one to eight per animal, the average. rat possessing
three.

Dimensions measured were the longest diameter
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and the diameter perpendicular to this axis and parallel
to the ventral surface.

All tumors were mapped for fu-

ture identification.
Bilateral ovariectomy was performed.
tumor was then selected for biopsy.
fatty tissue were removed.

The largest

Skin and surrounding

A large tumor sample ( > 1 g.)

was weighed, frozen in acetone-dry ice, and s_tored at
-20° C for future receptor assays.

A smaller sample

(about 100 mg.) of the same tumor was used for enzyme
studies.
Glucose-6-Phosphate Dehydrogenase Assay
The small biopsy material was weighed and homogenized
in physiological saline containing 6.6 x 10- 4 M disodium
EDTA, 0.04 ml. per mg. of tissue.

Homogenization was ac-

complished by two minutes of mechanical pulverization with
a 7 ml. glass homogenizer embedded in ice.

The homogenate

was then centrifuged at 4° for ten minutes at 20,000 g.·
The supernatant was decanted and assayed for G6PD activity
according to the procedure of Lohr and Waller (70) as follows:
Three cuvettes were used for each sample:
ence and two experimental replicates.

one refer-

Into each cuvette

was pipetted 2.8 ml. triethanolamine buffer consisting of
0.9% triethanolamine hydrochloride in a 2% aqueous solution
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of disodium EDTA; adjusted to pH 7.5.
by 0.1 ml. sample supernatant.

This was followed

The replicate cuvettes

then received 0.05 ml. NADP (0.03 Min 1% sodium bicarbonate), while an equivalent volume of buffer was added
to the reference cuvette.

An incubation period of five

minutes was allowed for equilibration.

After this time

had elapsed, 0.05 ml. glucose-6-phosphate (0.04 M) was
added to all cuvettes.
Spectrophotometric measurement of G6PD activity is
based on the increase in absorbance which follows the reduction of NADP to NADPH.

Absorbance at 340 nm. was re-

corded for all cuvettes at one-minute.intervals during a
ten-minute period, using an LKB Biochrom 4050 ultraspectrophotometer.

Changes in absorbance of the reference

cuvette (usually negligible) were subtracted from those
of the experimental replicates.

Enzyme activity was cal-

culated in terms of Wroblewski units by the formula:
11 E

340

/ min.

- - - - - - - - x 10 (dilution factor)= G6PD units/ml.
0.001
Because of tumor heterogeneity, it was necessary to
determine specific enzyme activity, and a protein assay
was performed on the remaining homogenate.

Bradford's

method (71), based on the staining reaction of Coomassie
Brilliant Blue (Bio-Rad, Richmond, CA), was employed.

(This
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technique has certain advantages over the Lowry method
for protein determination in that only one reagent is
necessary, incubation time can be as short as five minutes, and only one wavelength is required for all spectrophotometric readings.)

Bovine serum globulin (Sigma

Chemical Co., St.-Louis, MO) was used as standards.

Speci-

fic enzyme activity was expressed as Wroblewski units per
mg. protein.
Follow-Up
After surgery, all surviving animals were examined
weekly, and their tumors were measured as described above.
Since a considerable portion of tumor ·had been removed
during biopsies, measurements taken one week following
ovariectomy were used as a basis for assessing tumor regression.

Because some of the frozen biopsies were very

large and extended along the length of the longer axis,
measurement of this long diameter only was employed for
these tumor comparisons.

In the case of other biopsied

and all non-biopsied tumors, the geometric mean of the
two diameters was used in estimations of size.

Hence,

evaluation of tumor size is always linear.
In order to distinguish clearly between regressing
(hormone-dependent) and non-regressing (hormone-independent)
tumors, certain criteria were established.

A tumor could be
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designated as hormone-dependent if its decrease in size
between the first and third week post-operative was at
least 15%, provided that thi·s decline was continuous·,
Necrotic tumors were excluded from consideration.

fur-

thermore, animals had to remain heal thy for thei1c tumors·
to be included in this category.

Tumors which continued

to grow were considered non-responsive to hormonal ab.,lation and, therefore, classified as hormone-:independent.
Animals were observed for three to eighteen weeks
following surgery.

Resumption of growth in previously•

reqressing tumors was measured and recorded.
At the end of this observation period, all animals
were sacrificed by means of ether asphyxiation.

Small

samples (about 100 mg,} of the originally biopsied tumors
(if they had not regressed completely} were assayed forG6PD activity as previously described,
Data Evaluati·on
All data obtained in this study were processed i·n
conformance with accepted procedures for, one-way analysis
of variance and statistical correlation (72) •

The ONEWAY

and SCATTERGRAM programs of the Statistical Package fo.r the
Social Sciences ( SPSS} were employed respectively (_7 3 }_,
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RESULTS
Of a total of 56 biopsied tumors·which were observed
for at least three weeks following surgery, 48 were categorized as either hormone dependent-or hormone independent.

The remainder did not fit into the classification

scheme described earlier, i. e., some became necrotic, etc.
As illustrated in Table 5, there is no significant difference in size between the hormone-dependent and autonomous tumors prior to ovariectomy.
The basis for determination of hormo.ne dependency is
tumor regression following ovariectomy.

These data are

expressed in Table 6 as size of tumor three weeks postsurgery.

The hormone-dependent group exhibited highly

significant regression (p

<

.001), while the hormone-in-

dependent tumors continued to grow.
Twenty-seven, or 56% of the 48 tumors were classi·fied as hormone dependent.

This percentage is lower than

that generally reported for DMBA-induced rat mammary cancer and may represent a biased sampling.

Each tumor se-

lected for biopsy was the largest one growing in that
particular animal.

The geometric means of the diameters

were, on the average, over 2 cm.

A sampling consisting

of large tumors is likely to contain a disproportionate
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number of aggressive, autonomous neoplasms.

Some of the

hormone-dependent tumors resumed growth in subsequent weeks,
suggesting a tendency to become autonomous.

Table 5.

Size of Biopsied Tumors at .Ovariectomy
(Data represent mean± standard.error.)

Group

Size in Centimeters

Hormone Dependent

2.3519 +
- 0.151 (N

=

27)

Hormone Independent

2.3771 + 0.145 (N

=

21)

Total

2.3629 + 0.105 (N

=

48)

Table 6.

n. s.

Size of Biopsied Tumors Three Weeks
Post-Ovariectomy

Group

Size in Centimeters

Hormone Dependent

1.3522 + 0.133 (N

=

27)

Hormone Independent

2.7943 + 0.193 (N

=

21)

Total

1.9831 +
- 0.153

=

48)

(N

p < .001
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Evaluation of the average initial size of all tumors,
not only those which were biopsied and assayed for enzyme
activity, is shown in Table 7.

Of 118 tumors, 90, or

about 76% proved to be hormone dependent, a ratio. more
in line with that generally obtained for this type of tumor.
It should be observed that there is a significant difference
in pre-operative size between the two groups, the hormonedependent tumors tending to be smaller (P <.05).

Table 7.

Size of All Tumors at Ovariectomy

Size in Centimeters

Group

+ 0.077 (N = 90)

Hormone Dependent

1. 7302

Hormone Independent

2.0743 + 0.150 (N = 28)

Total

1.8119 +
- 0.069 (N = 118)

Table 8.

p < -05

Size of All Tumors Three Weeks Post-OVariectomy

Group

Size in Centimeters

Hormone Dependent

0.8270 + 0.076 (N = 90)

Hormone Independent

2.5054 + 0.177

Total

1.2253 + 0.097 (N = 118)

(N = 28)

p

<

.001
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Considering all tumors, the hormone-dependent cancers
regressed in the three weeks following surgery, while the
autonomous neoplasms grew larger.

(See Table 8.)

The

sharp decline (over 50%) in average size for the hormonedependent group reflects the complete disappearance of
many of the smaller cancers.

About one third of all re-

gressing tumors showed evidence of recurrence in the succeeding period of observation.

Of the 44 animals with

multiple lesions, 15, or 34% possessed both hormone-de~
pendent and independent tumors.
Table 9 indicates the specific G6PD activity at the
time of surgery of those biopsied tumors for which such
measurements could be obtained.

The mean enzyme activity

of the hormone-dependent tumors is about twice that of.
the hormone-independent group, and this difference is highly
significant (p < .001).
Specific enzyme activity of these tumors at the time
the animals were sacrificed is recorded in Table 10.

The

smaller number of hormone-dependent tumors at this later
time is indicative of the total regression of some tumors
and the resumption of growth by some others.

The latter

group could no longer be designated as hormone dependent.
Enzyme activity of the hormone-dependent and independent
tumors is not significantly different at the time of
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sacrifice.

It is interesting to note that the G6PD ac-

tivity of hormone-dependent tumors in the weeks following
ovariectomy (Table 10) was almost identical to the activity
of hormone-independent tumors at the time of surgery
(Table 9).

Figure 3 is a graphic illustration of G6PD

activity of both groups of tumors before and after ovariectomy.

Table 9.

G6PD Activity of Tumors at Ovariectomy_

Group

Specific Enzyme Activity
(G6PD Units/mg. Protein)

Hormone Dependent

28.47 + 2.48 (N = 23)

Hormone Independent

14. 05 + 2.48 (N = 18)

Total

22.14 + 2.08

Table 10.

p

<

.001

(N = 41)

G6PD Activity of Tumors 3-18 Weeks
Post-Ovariectomy

Group

Specific Enzyme Activity
(G6PD Uni ts/mg. Protein)

Hormone Dependent

14.07 + 3.17 (N = 12)

Hormone Independent

11. 96 + 1. 80 (N = 18)

Total

12.80 + 1.64 (N = 30)

n.s.
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Post-Ovariectomy

Pre-Ovariectomy

p < .001
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p >

.s

/
20 _

G6PD Units
per
mg. Protein

/

10 -

Hormone
Dependent
N = 23

Figure 3.

Hormone
Independent
N

= 18

Hormone

Hormone

Dependent

Independent

N = 12

N = 18

Specific G6PD Activity
Lines (I) delimit mean~ standard error.
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Data for the hormone-dependent tumors were analyzed
to determine whether there was any correlation between
G6PD activity and percentage of regression (adjusted by
logarithmic transformation) between the first and third
week post-operative.

A positive correlation coefficient

of 0.29 was obtained, which was not statistically significant (.05 < p < .1).
Of the original group of biopsied hormone-dependent
tumors, five exhibited.definite indications. of regrowth
at some point following the third week post-operative assessment.

No differences in G6PD activity between the

recurring and non-recurring tumors could be detected either
at the time of'surgery (Table 11) or when the animals were
sacrificed (Table 12).
The recurring tumors were also analyzed to determine
a possible relationship between .G6PD activity and time
until resumption of growth.

The five tumors seemed to

demonstrate some positive correlation (r

=

0.77) between

enzyme activity and number of weeks in remission (range

=

4-8 weeks).

However, this correlation was not statis-

tically significant (. 05 < p

<

.1) in this small sample.
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Table 11.

G6PD Activity of Recurring and Non-Recurring
Hormone-Dependent Tumors at Ovariectomy

Group

Specific Enzyme Activity
(G6PD Units/mg. Protein)

Recurring

29.00 +
- 3. 80

(N

=

5)

Non-Recurring

28.84 + 3.16

(N

=

17)

Total

28.88 + 2.56

(N

=

22)

Table 12.

n.s.

G6PD Activity of Recurring and Non-Recurring
Hormone-Dependent Tumors Post-Ovariectomy

Group

Specific Enzyme Activity
(G6PD Units/mg. Protein)

Recurring

13.96 + 5.95 (N

=

5)

Non-Recurring

14.07 + 3.17 (N

=

12)

Total

14. 04 + 2.63 (N

=

17)

n.s.
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DISCUSSION
For the purpose of this study, a hormone-dependent
cancer is considered to be one which must be supplied with
estrogen in order to continue self-maintenance, while an
autonomous tumor has no such requirement.

If a tumor is

dependent upon estrogen, it should regress after ovariectomy, as was the case for 76% of the DMBA-induced rat mammary tumors in this study (Table 8).
That the level of G6PD activity was significantly
higher (p < .001) among the hormone-dependent tumors than
the hormone-independent ones prior to ovariectomy (Table 9)
is an indication of an intact estrogen-receptor-protein
synthesis system in the former group.

These results are

consistent with the findings of Ringler and Hilf (57) and
Briand and Daehnfeldt (60), who used rodent models.

Studies

based on human cancers (62-66) offer conflicting results.
However, these investigations compare G6PD activity with
estrogen receptor which, by itself, is not a very accurate
predictor of hormone dependency.

Human breast cancers must

be followed for several years to determine whether future
recurrences are responsive to hormonal manipulation, and,
to date, no sequential studies have been reported.
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While hormone-dependent tumors in this study demonstrate G6PD activity very significantly higher than do the
hormone-independent tumors prior to endocrine ablation, the
range of enzyme activity is a continuum, i . e . , there is no
sharp demarcation between h:Lgh and low levels of activity;
If the median value is arbitrarily chosen as a dividing
line between high and low levels of G6PD activity, about
85% of the members of the higher group represent hormonedependent tumors.

Perhaps repeated experiments could ul-

timately furnish a standard for establishing high and low
levels of activity, relating them to hormone dependency.
In this regard, standards for determining estrogen or progesterone receptor status are not quite uniform; lower
limits for positive assessment have ranged from 3 to 20
fmoles per mg. protein•.
Upon further examination of the distribution of G6PD
activity, it was observed that a considerable proportion
of tumors (about 25%} in the lower half of the curve were
hormone dependent.

Unfortunately, increasing the relia-

bility of a test often decreases its sensitivity and increases the likelihood of false-negative results.
effect can be observed in receptor evaluations.

This
Although

progesterone receptor assay determinations have improved
the chances of predicting hormone dependency, as indicated
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in Table 3, over 30% of ER+ tumors lacking progesterone
receptor respond to endocrine therapy.
Possibly a multifactorial approach to predicting
hormone dependency could be developed, and an index of
predictor values established.

Besides progesterone re-

ceptor and G6PD, enzymes, such as lactose synthetase (64)
and a peroxidase (74), have been found to be synthesized
by breast cancers in response to estrogen stimulation.
Additional pr_oteins have ·recently been isolated and suggested as markers for hormone dependency (75-78).
The importance of accurate prediction of hormone dependency has increased with the development of a greater
variety of aggressive treatments for primary breast cancer.
Stage II primary carcinoma, where axillary lymph nodes show
signs of metastasis, are usually presumed to have produced
undetectable distal micrometastases as well, which can be
controlled by chemotherapy (4).

The newer forms of hor-

monal manipulation, such as anti-estrogens, are appropriate
primary treatment for hormone-dependent cancer, and clinical
trials of adjuvant hormonal therapy have been conducted.
Among the findings of the National Surgical Adjuvant Breast
and Bowel Project (NASBP) were lower survival rates for
younger patients lacking estrogen and/or progesterone receptors when treated with tamoxifen and conventional chemotherapy than with chemotherapy alone (79).

It was suggested
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that tamoxifen may alter the metabolism of chemotherapeutic agents by affecting the liver.

If anti-estrogens

do, in fact, interfere with other forms of therapy, proper
evaluation of hormone dependency is obviously essential.
A lack of significant correlation between enzyme activity and percentage of regression between the first and
third week post-operative may be due to the presence of
other variables, such as original tumor size, and by the
arbitrary time limit which was imposed.

Some tumors which

had regressed only moderately during the two-week period
demonstrated greater diminution in succeeding weeks.
Levels of G6PD activity for hormone-dependent cancers
declined considerably following ovariectomy (Table 10),
since the estrogen supply required for the synthesis of
substantial amounts of this protein was drastically curtailed.

This decrease in enzyme activity is in

agreement

with the results obtained by Bodwin and Cho-Chung (67) and
by Nicholson (68).
In contrast, the low enzyme activity of the hormoneindependent tumors hardly exhibited any decrease after
surgery.

Figure 3 compares the G6PD activity of the two

groups of tumors before and after ovariectomy.

The non-

significant decline which did occur among tne autonomous
group can possibly be attributed to small sub-populations
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of cells within the tumor which retained hormone dependency and which, consequently, were deprived of estrogen-stimulated G6PD synthesis by ovariectomy.

Con-

versely, it is likely that within a hormone-dependent
tumor there are subsets of cells which have lost their
ability to respond to estrogen and which form the nucleus
of a recurring autonomous tumor.
Unfortunately, only five definite cases of growth
resumption could be detected among the assayed, originally hormone-dependent tumors.

Undoubtedly, had the

animals been permitted to survive longer, more recurrences would have been observed.

The recurring tumors

expressed the same enzyme activity as the non-recurring
ones both before and after ovariectomy (Tables 11 and 12).
If a high level of G6PD activity is indicative of
hormone dependency, the sharp decline in enzyme activity
following surgery would seem to diminish the likelihood
of a differentiated, hormone-dependent population regrowing
in response to extra-ovarian sources of estrogen.

Hence,

these findings tend to refute the stem cell hypothesis of
Selby et al.

(22) and to lend support to the clonal se-

lection model (20) of a differentiated cell line progressing
to autonomy.

Since the number of assayed recurring tumors

in this study is admittedly small, it would be premature to
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form any definite conclusions based on these results.
A significant association between G6PD activity and
length of remission could not be determined for the recurrent group.

Perhaps a larger sample would have es-

tablished a more definite relationship.
This study would seem to furnish strong evidence indicating a higher level of G6PD activity among hormonedependent rat mammary tumors than among autonomous neoplasms in response to ovarian'stimulati"on.

Assay of tumors·

for G6PD activity may therefore be a valuable tool in predicting hormone dependency.
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SUMMARY
Glucose-6-phosphate dehydrogenase (G6PD) is an enzyme
whose synthesis in rat mammary tumors has been shown to be
promoted by estrogen.

Assays of G6PD activity can be em-

ployed to determine whether the steroid action mechanism
is functioning, an indication of hormone dependency.
In this study, hormone-dependent tumors yielded higher
levels of G6PD activity than did autonomous neoplasms.

Re-

moval of the primary estrogen source through ovariectomy
resulted.in a substantial decline in enzyme activity in
the former group but little change in the latter, lending
support for the role of estrogen in the regulation of G6PD
activity.
A high level of G6PD activity can be regarded as a
valid indicator of hormone dependency.

It is suggested

that a battery of assays encompassing this enzyme and other
proteins whose synthesis is stimulated by estrogen could be
established to improve predictions of hormone dependency
and the management of breast cancer.
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